Abstract

9032 Background: Three phase II trials have shown an overall response rate (ORR) around 20% with imatinib in melanoma carrying KIT mutations. The aim of this study was to study the interest of nilo...

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title
Journal
Date
Author
Current advances and perspectives in the treatment of advanced melanoma
Elisabeth Livingstone ... Lisa Zimmer
JDDG | VOL. 10
Elisabeth Livingstone, et. al.Elisabeth Livingstone ... Lisa Zimmer
20 Mar 2012
A phase II study of biochemotherapy for the treatment of metastatic malignant melanoma
P Gibbs ... M Becker
Melanoma Research | VOL. 10
P Gibbs, et. al.P Gibbs ... M Becker
01 Apr 2000
The efficacy and safety assessment of oncolytic virotherapies in the treatment of advanced melanoma: a systematic review and meta-analysis
Changyuan Wang ... Yang Li
Virology journal | VOL. 20
Changyuan Wang, et. al.Changyuan Wang ... Yang Li
02 Nov 2023
Phase II multicentric uncontrolled national trial assessing the efficacy of nilotinib in the treatment of advanced melanomas with c-KIT mutation or amplification: Results of the pharmacodynamic study.
Elodie Lesteven ... Stephane Dalle
Journal of Clinical Oncology | VOL. 33
Elodie Lesteven, et. al.Elodie Lesteven ... Stephane Dalle
20 May 2015
View more papers

More From: Journal of Clinical Oncology

Paper Title
Journal
Date
Author
Tailored Dose-Dense Versus Standard Adjuvant Chemotherapy for High-Risk Early Breast Cancer: End-of-Study Results of the Randomized PANTHER Trial.
Alexios Matikas ...
Journal of Clinical Oncology | VOL. -
Alexios Matikas, et. al.Alexios Matikas ...
17 Jul 2024
Lymphoma Classifications, How to Develop a Future Unified Taxonomy.
Elias Campo ... Reiner Siebert
Journal of Clinical Oncology | VOL. -
Elias Campo, et. al.Elias Campo ... Reiner Siebert
17 Jul 2024
Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis Attenuates Disparity in Outcomes Between Use of Matched or Mismatched Unrelated Donors.
Brian C Shaffer ... Monzr M Al Malki
Journal of Clinical Oncology | VOL. -
Brian C Shaffer, et. al.Brian C Shaffer ... Monzr M Al Malki
17 Jul 2024
Genetic Counseling, Testing, and Family Communication Into Survivorship After Diagnosis of Breast Cancer.
Steven J Katz ... Allison W Kurian
Journal of Clinical Oncology | VOL. -
Steven J Katz, et. al.Steven J Katz ... Allison W Kurian
15 Jul 2024
View more papers